ArticleJournal for immunotherapy of cancer2026

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.

Changhoon Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.